CVD prevention and event reduction.

27 August 2017 (12:50 - 13:10)

Organised by:

About the speaker

Professor Marc Sabatine

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail

Introduction - PCSK9 inhibitors: the next chapter in CVD prevention.

Presentation thumbnail

Future perspectives in lipid lowering and CVD prevention.

Professor P. Sever (London, GB)

Presentation thumbnail

Panel discussion - PCSK9 inhibitors: the next chapter in CVD prevention.

Professor J. Chapman (Paris, FR)

Presentation thumbnail

Close - PCSK9 inhibitors: the next chapter in CVD prevention.

Professor J. Chapman (Paris, FR)

Access the full session

Session thumbnail

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in cardiovascular disease prevention

The Event

ESC Congress 2017

27 August 2017 12:50 CET

You may be interested in

Webinar

Personalised CVD prevention: the evidence behind the current guidelines. ESC 2021 Clinical Practice Guidelines - Webinar Series

23 June 2022

Congress Presentation

The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe

28 August 2022

Congress Presentation

Saving hearts, extending lives: the impact of risk prevention on lifetime estimates in Germany

29 August 2025

Congress Presentation

Reduction of cardiovascular events in patients with cardiovascular disease with the CV-polypill: a retrospective and propensity score matching study

27 August 2021

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources